MGAT3 and inflammatory bowel disease: It is worth noting that the same pattern of CpG methylation differences was observed in PBMCs of the IBD patients and HC from both large independent cohorts, and most of the CpG sites within the assayed portion of the MGAT3 promoter were also differentially methylated in CD19+ B cells from the subset of IBD patients from the Edinburgh cohort (Fig. 2a, b).